Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol + spironolactone
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination medication used primarily for feminizing hormone therapy (FHT) in transgender women. Estradiol provides feminizing effects through estrogen activity, while spironolactone works as an antiandrogen by blocking testosterone receptors and reducing testosterone production. This combination helps develop female secondary sex characteristics while suppressing male characteristics.
02
Targets
ESR2 (ERβ)AR (Adrenergic receptors)ESR1 (ERα)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on estradiol + spironolactone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol + spironolactone.